Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

CJC-1295

gh-releasemusclerecovery
Regulatory status — Research use only — not approved for human use

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered with a maleimido group that enables covalent binding to plasma proteins, substantially extending its duration of action compared to native GHRH. It is prohibited by the World Anti-Doping Agency (WADA) and holds no approved indication from the FDA, EMA, or any comparable regulatory body. The peer-reviewed evidence base for CJC-1295 in humans consists entirely of doping-detection methodology, regulatory commentary, and descriptive community-use reports — no human clinical trials evaluating efficacy, safety, or pharmacokinetics are present in the current research packet.

Evidence coverage

22/28 claims verified by independent fact-checker.

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
[insufficient evidence in research packet]
Frequency
[insufficient evidence in research packet — no human trial data available]
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via —.
  • Evidence base: animal model studies.
  • Primary goals: gh-release, muscle, recovery.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

GHRH analogues stimulate pulsatile GH release from the pituitary, elevating IGF-1 and promoting fat oxidation.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that acts on pituitary somatotroph cells to stimulate growth hormone (GH) secretion [8] [1] [2]. What distinguishes CJC-1295 from earlier GHRH analogs is the incorporation of a maleimido group at its C-terminus, which enables covalent binding to plasma proteins such as serum albumin [1] [2]. Analytical chemistry studies in equine plasma indicate that this protein-conjugation mechanism confers a markedly prolonged duration of action — preliminary evidence from detection methodology research suggests CJC-1295 may stimulate GH production for more than six days following a single administration, in contrast to the much shorter activity window of unconjugated peptides [1] [2]. These mechanistic observations derive from analytical and equine studies; no human pharmacokinetic or pharmacodynamic studies are present in the current research packet.

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Regulatory awareness
  • Understand that CJC-1295 is not approved by the FDA, EMA, or any comparable regulatory authority for any human indication
  • Understand that CJC-1295 is prohibited by WADA in sanctioned sport [3] [4]
Evidence review
  • Recognize that no human RCT data on efficacy, safety, dosing, or pharmacokinetics for CJC-1295 are present in the current research packet
  • Consult a licensed physician before considering use of any unapproved peptide compound [15]
  • [insufficient evidence in research packet — no human clinical trial data available to support pre-cycle preparation guidance]

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • [insufficient evidence in research packet — no human clinical trial data available to support in-cycle monitoring guidance]

After — Post-cycle

  • [insufficient evidence in research packet — no human clinical trial data available to support post-cycle guidance]

Stacks it appears in

CJC-1295 is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with CJC-1295. Educational context only.

Hexarelin

Tier 3
gh-releaserecovery

MK-677

Tier 2
gh-releasemuscle

BPC-157

Tier 3
recovery

DSIP

Tier 2
recovery

Safety

Common side effects

  • ·[insufficient evidence in research packet — no human safety studies identified]

Rare side effects

  • ·[insufficient evidence in research packet — no human safety studies identified]
Safety notice — Serious / theoretical risks:
  • [insufficient evidence in research packet — no human safety studies identified]

Contraindications

  • ·[insufficient evidence in research packet — no human clinical contraindication data identified]

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for CJC-1295. Be the first to share yours.

Share your experience →

Have you tried CJC-1295?

Share your protocol and outcome to help build the community dataset.

Share your experience →

CJC-1295 — at a glance

PropertyCJC-1295—
Half-life——
Route——
Typical doseSee research context—
MechanismCJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that acts on pituitary somatotroph cells to stimulate growth hormone (GH) secretion. What distinguishes CJC-1295 from earlier GHRH analogs is the incorporation of a maleimido group at its C-terminus, which enables covalent binding to plasma proteins such as serum albumin. Analytical chemistry studies in equine plasma indicate that this protein-conjugation mechanism confers a markedly prolonged duration of action — preliminary evidence from detection methodology research suggests CJC-1295 may stimulate GH production for more than six days following a single administration, in contrast to the much shorter activity window of unconjugated peptides. These mechanistic observations derive from analytical and equine studies; no human pharmacokinetic or pharmacodynamic studies are present in the current research packet.—
Evidence strengthanimalanecdotal
Primary goalgh-release—

Frequently asked questions

What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered with a maleimido group that enables covalent binding to plasma proteins. This modification substantially extends its duration of action compared to native GHRH. It is not FDA-approved and is classified as a research compound.
How does CJC-1295 work?
CJC-1295 acts on pituitary somatotroph cells to stimulate growth hormone secretion via GHRH receptors. Its maleimido modification enables covalent binding to circulating plasma proteins, dramatically prolonging its biological half-life compared to native GHRH and earlier analogs.
What is CJC-1295 used for?
CJC-1295 has been investigated as a research compound for its growth hormone secretagogue properties. No controlled human clinical trials have established its safety or efficacy for any indication, and it does not hold regulatory approval in any jurisdiction.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved for any indication. It is classified as a research compound without established safety or efficacy data from controlled human trials.
What are common dosages of CJC-1295?
No human clinical dosing data have been established for CJC-1295. No approved dose or frequency has been identified from the available research literature. The research packet documents insufficient evidence to identify a human dosing protocol.
How is CJC-1295 administered?
No validated route of administration has been established for CJC-1295 in human clinical research. The research packet documents insufficient evidence to confirm a route based on human trial data.
What are common side effects of CJC-1295?
No controlled human trial data exist to characterize the side-effect profile of CJC-1295. Its safety in humans has not been established from clinical research.
Is CJC-1295 prohibited in competitive sport?
Yes. CJC-1295, as a GHRH analog, is prohibited by the World Anti-Doping Agency (WADA). Athletes subject to anti-doping testing should not use CJC-1295.
Are there safety concerns with CJC-1295?
Because no human clinical trials have been conducted, the safety profile of CJC-1295 is unknown. No contraindications from human data could be identified in the current research literature.
Can CJC-1295 be combined with other peptides?
No evidence-supported combination protocols have been established for CJC-1295. No stacking combinations with human-validated data were identified in the current source literature.
Is CJC-1295 legal?
CJC-1295 is not FDA-approved and is not a scheduled controlled substance in the United States. Its legal status for possession and sale varies by jurisdiction. This is not legal advice — consult applicable regulations in your area.
How does CJC-1295 differ from sermorelin?
Both CJC-1295 and sermorelin are synthetic GHRH analogs that stimulate growth hormone secretion via pituitary GHRH receptors. CJC-1295's maleimido modification enables plasma protein binding and dramatically extends its biological half-life. Sermorelin has documented diagnostic applications in children; CJC-1295 has no approved clinical use.

References

  1. [1]

    A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

    Timms Mark, Ganio Katherine, Steel Rohan

    Drug testing and analysis · 2019 · PMID 30938069

  2. [2]

    An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

    Timms Mark, Ganio Katherine, Forbes Grace et al.

    Drug testing and analysis · 2019 · PMID 30489688

  3. [3]

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    Uçaktürk Ebru, Nemutlu Emirhan

    Journal of pharmaceutical and biomedical analysis · 2026 · PMID 41138283

  4. [4]

    Advances in the detection of growth hormone releasing hormone synthetic analogs.

    Memdouh Siham, Gavrilović Ivana, Ng Kelsey et al.

    Drug testing and analysis · 2021 · PMID 34665524

  5. [5]

    Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

    Pont Laura, Alechaga Élida, Terrero Alejandro et al.

    Journal of chromatography. A · 2020 · PMID 32971474

  6. [6]

    Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

    Thomas Andreas, Walpurgis Katja, Tretzel Laura et al.

    Drug testing and analysis · 2015 · PMID 26382721

  7. [7]

    Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

    Thevis Mario, Thomas Andreas, Schänzer Wilhelm

    Expert review of proteomics · 2014 · PMID 25382550

  8. [8]

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Rahman Omar F, Lee Steven J, Seeds William A

    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 · PMID 41490200

  9. [9]

    Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

    Cristea Cătălina-Diana, Radu Mihai, Toboc Ani et al.

    Analytical biochemistry · 2023 · PMID 37806509

  10. [10]

    An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

    Coppieters Gilles, Deventer Koen, Polet Michaël et al.

    Journal of pharmaceutical and biomedical analysis · 2022 · PMID 35298973

  11. [11]

    Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

    Knoop Andre, Thomas Andreas, Fichant Eric et al.

    Analytical and bioanalytical chemistry · 2016 · PMID 26879649

  12. [12]

    Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

    Van Hout Marie Claire, Hearne Evelyn

    Substance use & misuse · 2016 · PMID 26771670

  13. [13]

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    Coutinho Luis F D, DE Oliveira Neves Lucas F, Camilo Rafael P

    The Journal of sports medicine and physical fitness · 2026 · PMID 41880199

  14. [14]

    Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

    Thomas Andreas, Walpurgis Katja, Thevis Mario

    Journal of mass spectrometry : JMS · 2024 · PMID 38197510

  15. [15]

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Mendias Christopher L, Awan Tariq M

    Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

  16. [16]

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    Mayfield Cory K, Bolia Ioanna K, Feingold Cailan L et al.

    The American journal of sports medicine · 2026 · PMID 41476424

  17. [17]

    The study of doping market: How to produce intelligence from Internet forums.

    Pineau Thomas, Schopfer Adrien, Grossrieder Lionel et al.

    Forensic science international · 2016 · PMID 27710891

  18. [?]

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Mavrych Volodymyr, Shypilova Inna, Bolgova Olena

    Frontiers in aging · 2026 · PMID 42021992

  19. [?]

    Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

    Thomas Andreas, Thilmany Sam, Hofmann Amelie et al.

    Analytical science advances · 2022 · PMID 38716080

  20. [?]

    Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

    Danila George Madalin, Puiu Mihaela, Zamfir Lucian-Gabriel et al.

    Talanta · 2022 · PMID 34736642

Compare CJC-1295 with…

CJC-1295 vs Hexarelin vs Ipamorelin

CJC-1295 · Hexarelin · Ipamorelin

View comparison →